Site Editor
Sandy Srinivas, MD
Sandy Srinivas, MD
Posted: Monday, October 9, 2023
Enzalutamide combined with leuprolide acetate and enzalutamide monotherapy clinically improved metastasis-free survival rates in patients with high-risk biochemically recurrent prostate cancer who had prior radiotherapy, suggesting a potential new standard-of-care approach. These findings from a subgroup analysis of the phase III EMBARK trial were presented at the 2023 American Society for Radiation Oncology (ASTRO) Annual Meeting (Abstract LBA 06). However, further research is warranted to confirm whether this combination therapy would be of benefit in patients who had not received prior radiotherapy, explained Swetha Sridharan, MBBS, of Calvary Mater Newcastle Hospital, United Kingdom, and colleagues.
A total of 804 patients with high-risk biochemically recurrent prostate cancer were recruited for the study. All patients had received previous radiotherapy. Patients were stratified to receive combination treatment with enzalutamide and leuprolide acetate (n = 265), enzalutamide monotherapy (n = 256), or combination treatment with leuprolide acetate and a placebo (n = 283). Patients had their prostate-specific antigen levels assessed regularly. In addition, 264 patients with high-risk biochemically recurrent prostate cancer who never received radiotherapy were also stratified to receive the aforementioned treatments (n = 90, n = 99, n = 75, respectively), and the results were compared with patients who received radiotherapy.
The study findings revealed that the rate of metastasis-free survival was increased for patients in the radiotherapy group who received combination therapy with enzalutamide and leuprolide acetate as well as for those administered enzalutamide monotherapy as compared with patients who received combined leuprolide acetate and placebo therapy. Patients with no history of radiotherapy treatment who received enzalutamide and leuprolide acetate combination therapy had superior rates of metastasis-free survival compared with patients who received combined leuprolide acetate and placebo therapy.
Disclosure: Dr. Sridharan reported no conflicts of interest.
JNCCN Spotlights
Resources
For your Patients
